BeiGene

#News for #Investors and #Media: Starting June 1, eligible patients in Croatia with chronic lymphocytic leukemia (#CLL) and Waldenström’s macroglobulinemia (#WM) now have access to our BTK inhibitor. Furthering our mission to bring our innovative medicines to more patients, we have expanded our footprint for this important treatment to 70 markets. 

That’s a wrap on #ASCO24. Every year, we are inspired by the cutting-edge oncology research that is presented and its potential to help patients.     As we close out the meeting, hear from #esophagealcancer patient Rich, as he shares his hope for what the future of clinical research holds for patients like him. https://bit.ly/3yrtEZ5

Today at #ASCO24, we are excited to be presenting new data on the relapsed / refractory chronic lymphocytic leukemia (#CLL) landscape. Alongside data from head-to-head clinical trials, this research will help to arm physicians with strong, clinically relevant data to help support decision-making for their patients. Learn more about our commitment to #bloodcancers like #CLL. https://bit.ly/3yrtEZ5

Our commitment to delivering innovative medicines to more patients worldwide is built on a deep understanding of the urgency of our work. We recognize achieving our mission depends not only on our colleagues' dedication but also on their ability to work better and live better. Our colleagues are able to perform at their best only when they can effectively manage their work and personal lives, which varies for each individual.     To support this, our "Work Better, Live Better" (WBLB) program offers resources and services designed to enhance and improve overall work, life and wellbeing. Our WBLB initiative focuses on helping our colleagues build proactive behaviors, develop an open and positive mindset, and create efficiencies, while digging deeper into what each needs to be at their very best.    Learn more about working at BeiGene: https://bit.ly/3yQzp2l

#News for #Investors and #Media: Our PD-1 inhibitor has been listed on the Australian Register of Therapeutic Goods as a treatment for unresectable oesophageal squamous cell carcinoma (#OSCC #ESCC) after prior chemotherapy, and as a first and second-line treatment for patients with locally advanced or metastatic squamous and nonsquamous* non-small cell lung cancer (#NSCLC). (*PD-L1 restrictions apply)

Come meet us at our #ASCO24 networking event on June 2, whether you’re interested in career opportunities at BeiGene or simply looking to broaden your professional network. Don’t miss out on this opportunity to connect with #biotech professionals and discover what BeiGene has to offer. Hope to see you there!

Tomorrow is the first day of #ASCO24 and we’re looking forward to seeing exciting new data from the global #oncology community.     If you’re here in Chicago, be sure to stop by Booth 12075 and visit our online hub for information on everything we have planned. https://bit.ly/3yrtEZ5

#News for #Investors and #Media: Our BTK inhibitor has been approved in Saudi Arabia for the treatment of adult patients with Waldenström's macroglobulinemia (#WM), marginal zone lymphoma (#MZL), and chronic lymphocytic leukemia (#CLL) or small lymphocytic lymphoma (#SLL).   This represents an exciting step forward for patients in the country, where #bloodcancers are among the top five most prevalent #cancers, including #lymphoma and #leukemia.

Join us as we bring together leading oncology experts for a virtual panel discussion about the #BTKi treatment landscape for #CLL. Register now and log on at 12:35 PM ET on June 4 to hear the conversation. https://lnkd.in/e2bF64dS

Every 27 seconds, someone in the world is diagnosed with a #bloodcancer like lymphoma or leukemia. On #WorldBloodCancerDay, we celebrate the strength and resilience of patients, caregivers, and healthcare professionals against blood cancers and reinforce our commitment to improving the lives of the millions of people impacted by these diseases. Learn more about our research and development of targeted therapies for blood cancers: https://bit.ly/4bSeOJm